Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Large Growth in Short Interest

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the recipient of a large increase in short interest in February. As of February 15th, there was short interest totalling 1,810,000 shares, an increase of 809.1% from the January 31st total of 199,100 shares. Currently, 10.7% of the shares of the company are short sold. Based on an average daily trading volume, of 3,770,000 shares, the days-to-cover ratio is presently 0.5 days.

Institutional Investors Weigh In On Xilio Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of XLO. Aptus Capital Advisors LLC purchased a new position in shares of Xilio Therapeutics during the 4th quarter valued at $39,000. Raymond James Financial Inc. purchased a new position in shares of Xilio Therapeutics during the 4th quarter valued at $48,000. Trustees of Columbia University in the City of New York purchased a new position in shares of Xilio Therapeutics during the 4th quarter valued at $238,000. Geode Capital Management LLC grew its position in shares of Xilio Therapeutics by 85.0% during the 3rd quarter. Geode Capital Management LLC now owns 338,192 shares of the company’s stock valued at $266,000 after purchasing an additional 155,337 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in shares of Xilio Therapeutics by 11.4% during the 4th quarter. Renaissance Technologies LLC now owns 296,617 shares of the company’s stock valued at $283,000 after purchasing an additional 30,317 shares in the last quarter. Institutional investors own 54.29% of the company’s stock.

Xilio Therapeutics Trading Down 8.7 %

NASDAQ:XLO opened at $0.89 on Friday. The stock has a market capitalization of $39.21 million, a PE ratio of -0.52 and a beta of -0.30. The firm’s 50 day moving average is $0.98 and its 200 day moving average is $0.94. Xilio Therapeutics has a 12 month low of $0.58 and a 12 month high of $1.93.

Analyst Upgrades and Downgrades

Separately, Raymond James dropped their target price on shares of Xilio Therapeutics from $6.00 to $4.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.